AR123684A1 - Compuesto de tetrahidrobenzofurodiazepinona y uso farmacéutico del mismo - Google Patents

Compuesto de tetrahidrobenzofurodiazepinona y uso farmacéutico del mismo

Info

Publication number
AR123684A1
AR123684A1 ARP210102742A ARP210102742A AR123684A1 AR 123684 A1 AR123684 A1 AR 123684A1 AR P210102742 A ARP210102742 A AR P210102742A AR P210102742 A ARP210102742 A AR P210102742A AR 123684 A1 AR123684 A1 AR 123684A1
Authority
AR
Argentina
Prior art keywords
alkyl
atom
hydroxy
independently
cycloalkyl
Prior art date
Application number
ARP210102742A
Other languages
English (en)
Inventor
Masafumi Inoue
Yosuke Ogoshi
Takayuki Furukawa
Takuya Machida
Ikuo Mitani
Kazuhito Harada
Yuichi Nakagawa
Nobutaka Yamaoka
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR123684A1 publication Critical patent/AR123684A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula [1], o una sal aceptable para uso farmacéutico del mismo, caracterizado porque Cy¹ es (1) cicloalquilo C₃₋₇, (2) heterocicloalquilo de 4 a 7 miembros que contiene uno o dos heteroátomos seleccionados de manera independiente del grupo que consiste en átomos de oxígeno y azufre (el átomo de azufre puede estar oxidado), como un átomo que constituye el anillo además de los átomos de carbono, (3) cicloalquilo C₅₋₈ puenteado, (4) heterocicloalquilo puenteado de 7 a 9 miembros que contiene un átomo de oxígeno como un átomo que constituye el anillo además de los átomos de carbono, (5) espirocicloalquilo C₇₋₁₁, o (6) espiroheterocicloalquilo de 7 a 11 miembros que contiene de uno a tres átomos de oxígeno como un átomo que constituye el anillo además de los átomos de carbono; R¹ en el número de m son cada uno de manera independiente (1) halógeno, (2) hidroxi, (3) alquilo C₁₋₆ en el que el alquilo está sustituido de manera opcional con (a) hidroxi, (b) alcoxi C₁₋₄, (c) ciano, (d) OCOR¹¹ en el que R¹¹ es fenilo, o (e) SO₂R¹² en el que R¹² es alquilo C₁₋₄, (4) haloalquilo C₁₋₄ en el que el haloalquilo está sustituido de manera opcional con hidroxi, (5) alcoxi C₁₋₄ en el que el alcoxi está sustituido de manera opcional con 1 a 3 halógenos, (6) COR¹³ en el que R¹³ es (a) hidroxi, o (b) NR¹⁴R¹⁵ en el que R¹⁴ y R¹⁵ son cada uno de manera independiente hidrógeno o alquilo C₁₋₄, (7) ciano, (8) SO₂R¹⁶ en el que R¹⁶ es alquilo C₁₋₄, (9) cicloalquilo C₃₋₄ en el que el cicloalquilo está sustituido de manera opcional con hidroxi, o (10) triazolilo, o dos R¹ unidos al mismo átomo de carbono se toman juntos para formar oxo; R² en el número de n son cada uno de manera independiente (1) halógeno, o (2) alcoxi C₁₋₄, o dos R² unidos al mismo átomo de carbono se toman juntos para formar cicloalcano C₃₋₄ con el átomo de carbono al que están unidos; R³ y R⁴ son cada uno de manera independiente (1) hidrógeno, o (2) alquilo C₁₋₄, o R³ y R⁴ se toman juntos para formar cicloalcano C₃₋₄ con el átomo de carbono al que están unidos; R⁵ es hidrógeno o alquilo C₁₋₄; R⁶ es haloalquilo C₁₋₄; R⁷ es hidrógeno o halógeno; L es alquileno C₁₋₄ lineal; m es 0, 1, 2, 3 ó 4; y n es 0, 1, 2 ó 3.
ARP210102742A 2020-10-05 2021-10-04 Compuesto de tetrahidrobenzofurodiazepinona y uso farmacéutico del mismo AR123684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020168596 2020-10-05

Publications (1)

Publication Number Publication Date
AR123684A1 true AR123684A1 (es) 2023-01-04

Family

ID=81125276

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102742A AR123684A1 (es) 2020-10-05 2021-10-04 Compuesto de tetrahidrobenzofurodiazepinona y uso farmacéutico del mismo

Country Status (17)

Country Link
US (2) US11643417B2 (es)
EP (1) EP4227308A1 (es)
JP (1) JP2022061021A (es)
KR (1) KR20230083305A (es)
CN (1) CN116437927A (es)
AR (1) AR123684A1 (es)
AU (1) AU2021357608A1 (es)
BR (1) BR112023005024A2 (es)
CA (1) CA3196024A1 (es)
CL (1) CL2023000977A1 (es)
CO (1) CO2023005262A2 (es)
IL (1) IL301866A (es)
MX (1) MX2023003932A (es)
PE (1) PE20240065A1 (es)
TW (1) TW202229287A (es)
WO (1) WO2022075240A1 (es)
ZA (1) ZA202304169B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014324A2 (en) * 2000-08-16 2002-02-21 Warner-Lambert Company Diazepinones as antiviral agents
US20040116410A1 (en) 2001-08-07 2004-06-17 Hidetsura Cho Diazepinones as antiviral agents
TW200930375A (en) 2007-12-21 2009-07-16 Exelixis Inc Benzofuropyrimidinones

Also Published As

Publication number Publication date
WO2022075240A1 (ja) 2022-04-14
ZA202304169B (en) 2023-12-20
CO2023005262A2 (es) 2023-05-19
CA3196024A1 (en) 2022-04-14
US11643417B2 (en) 2023-05-09
CL2023000977A1 (es) 2023-09-29
US20220162220A1 (en) 2022-05-26
BR112023005024A2 (pt) 2023-04-18
IL301866A (en) 2023-06-01
PE20240065A1 (es) 2024-01-11
TW202229287A (zh) 2022-08-01
KR20230083305A (ko) 2023-06-09
US20240116943A1 (en) 2024-04-11
JP2022061021A (ja) 2022-04-15
AU2021357608A1 (en) 2023-06-08
CN116437927A (zh) 2023-07-14
EP4227308A1 (en) 2023-08-16
MX2023003932A (es) 2023-04-26

Similar Documents

Publication Publication Date Title
AR092742A1 (es) Piridinonas antifibroticas
AR116666A1 (es) Compuestos heterocíclicos
AR093036A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR114233A1 (es) 3-fenil-isoxazol-in-5-carboxamidas de derivados del ácido ciclopentenilcarboxílico con actividad herbicida
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
AR124117A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR103182A1 (es) Inmunomoduladores
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR093339A1 (es) Analogos de spliceostatina y metodos para su preparacion
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR092347A1 (es) Derivados de azaindol
AR092288A1 (es) Ligandos del receptor ep1
AR107359A1 (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
AR124379A1 (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
CR20170371A (es) Compuestos de benzoxaboral 4-sustituidos y uso de los mismos
AR093035A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR107361A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
AR075394A1 (es) Derivados del acido fenoxiacetico, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades inflamatorias,alergicas y neurodegenerativas.
AR089397A1 (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica
AR097719A1 (es) Compuestos heterocíclicos de n-acilimino
AR123684A1 (es) Compuesto de tetrahidrobenzofurodiazepinona y uso farmacéutico del mismo
AR117576A1 (es) Derivados de sulfinilaminobenzamida y sulfonilaminobenzamida